Risk-Based Anticoagulant Therapy (Modified From Section 4.1., Risk-Based Antithrombotic Therapy, in the 2014 AF Guideline) e130 4.1.1. Selecting an Anticoagulant Regimen Balancing Risks and Benefits (Modified From Section 4.1.1., Selecting an Antithrombotic Regimen Balancing Risks and Benefits, in the 2014 AF Guideline) e130 4.2. Anticoagulant Options (Modified From Section 4.2., Antithrombotic Options, in the 2014 AF Guideline) e134 4.3. Interruption and Bridging Anticoagulation e134 4.4. Nonpharmacological Stroke Prevention e135 4.4.1. Percutaneous Approaches to Occlude the LAA e135 4.4.2. Cardiac Surgery LAA Occlusion/ Excision e136 6. Rhythm Control e136 6.1. Electrical and Pharmacological Cardioversion of AF and Atrial Flutter e136 6.1.1. Prevention of Thromboembolism e136 6.3. AF Catheter Ablation to Maintain Sinus Rhythm e138 6.3.4. Catheter Ablation in HF e138 7. Specific Patient Groups and AF e138 7.4. AF Complicating ACS e138 7.12. Device Detection of AF and Atrial Flutter (New) e141 7.13. Weight Loss (New) e142 References e143 Appendix 1: Author Relationships With Industry and Other Entities (Relevant) e148 Appendix 2: Abbreviated Reviewer Relationships With Industry and Other Entities e150 PREAMBLE (FULL VERSION) Since 1980, the American College of Cardiology (ACC) and American Heart Association (AHA) have translated scientific evidence into clinical practice guidelines with recommendations to improve cardiovascular health. These guidelines, which are based on systematic meth- ods to evaluate and classify evidence, provide a founda- tion for the delivery of quality cardiovascular care. The ACC and AHA sponsor the development and publica- tion of clinical practice guidelines without commercial support, and members volunteer their time to the writ- ing and review efforts. Guidelines are official policy of the ACC and AHA. For some guidelines, the ACC and AHA partner with other organizations. 